Tag: AHA 2016

AHA 2016: Mortality rate with FFR-guided treatment of multivessel disease is...

The results of the FUTURE (Functional testing underlying revascularisation) trial indicate that the use of fractional flow reserve (FFR) to guide treatment—medical management, percutaneous...

AHA 2016: Heparin plus tirofiban is safe and effective for use...

A new study, by researchers from the Intermountain Medical Center Heart Institute (Salt Lake City, USA), indicates that there are no significant differences in...

AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients...

Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily dose of the drug and a P2Y12 inhibitor and...

AHA 2016: Elizabeth M McNally wins AHA prize for research into...

The American Heart Association (AHA) awarded its Basic Research Prize for 2016 to Elizabeth M McNally (Chicago, USA) for “Ground-breaking investigations of novel genetic...

AHA 2016: MOMENTUM 3 shows HeartMate 3 LVAD improves clinical outcomes...

The results of the MOMENTUM 3 US IDE clinical study, which were presented at a late-breaking clinical trial at the 2016 American Heart Association...

AHA 2016: Strong positive one-year data for Corvia Medical’s InterAtrial shunt...

Corvia Medical has announced one-year follow-up data from the REDUCE LAP-HF clinical study of its InterAtrial shunt device. The device is the world's first...

AHA 2016: Incomplete revascularisation after PCI increases risk of adverse events...

Ehrin J Armstrong (Section of Cardiology, Denver VA Medical Center and University of Colorado School of Medicine, Aurora, USA) and others report in JACC:...

AHA 2016: Two thirds of patients experience plaque regression with the...

Amgen has announced that adding its PCSK9 inhibitor evolocumab (Repatha) to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with...